Targovax is invited to present at upcoming investor conferences

Oslo, Norway, 21 January 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team will present at upcoming investor conferences.

Date: 22 January 2019
Venue: Redeye Fight Cancer Seminar, Stockholm, Sweden
Presenter: Erik Digman Wiklund (CBO)

Presentation:
–    Time: 10:45 CET

Panel discussion:
–    The field of Immuno-oncology – how to optimize clinical development – what trends do you see in the market?
–    Time: 11:40 CET

The event can be followed live here.
The presentation will be available to download at www.targovax.com after the event.

Date: 7 February 2019
Venue: 5th annual Immuno-oncology (IO) 360°, NYC, USA
Presenter: Erik Digman Wiklund (CBO)

Panel discussion:
–    Fundraising in the Current IO Space
–    Time: 11:10 AM EST

————————————————————————————-

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.